167 related articles for article (PubMed ID: 26271341)
21. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.
Cabelguenne A; Blons H; de Waziers I; Carnot F; Houllier AM; Soussi T; Brasnu D; Beaune P; Laccourreye O; Laurent-Puig P
J Clin Oncol; 2000 Apr; 18(7):1465-73. PubMed ID: 10735894
[TBL] [Abstract][Full Text] [Related]
22. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
Ock CY; Son B; Keam B; Lee SY; Moon J; Kwak H; Kim S; Kim TM; Jeon YK; Kwon SK; Hah JH; Lee SH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):873-83. PubMed ID: 26677030
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling.
Du L; Chen X; Cao Y; Lu L; Zhang F; Bornstein S; Li Y; Owens P; Malkoski S; Said S; Jin F; Kulesz-Martin M; Gross N; Wang XJ; Lu SL
Oncogene; 2016 Sep; 35(35):4641-52. PubMed ID: 26876212
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
Jin N; Keam B; Cho J; Lee MJ; Kim HR; Torosyan H; Jura N; Ng PK; Mills GB; Li H; Zeng Y; Barbash Z; Tarcic G; Kang H; Bauman JE; Kim MO; VanLandingham NK; Swaney DL; Krogan NJ; Johnson DE; Grandis JR
J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779417
[TBL] [Abstract][Full Text] [Related]
25. Molecular pathways in head and neck cancer: EGFR, PI3K, and more.
Psyrri A; Seiwert TY; Jimeno A
Am Soc Clin Oncol Educ Book; 2013; ():246-55. PubMed ID: 23714515
[TBL] [Abstract][Full Text] [Related]
26. Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features.
Rettig EM; Chung CH; Bishop JA; Howard JD; Sharma R; Li RJ; Douville C; Karchin R; Izumchenko E; Sidransky D; Koch W; Califano J; Agrawal N; Fakhry C
Cancer Prev Res (Phila); 2015 Apr; 8(4):287-95. PubMed ID: 25633867
[TBL] [Abstract][Full Text] [Related]
27. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
Redon R; Muller D; Caulee K; Wanherdrick K; Abecassis J; du Manoir S
Cancer Res; 2001 May; 61(10):4122-9. PubMed ID: 11358835
[TBL] [Abstract][Full Text] [Related]
28. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
[TBL] [Abstract][Full Text] [Related]
30. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
Azoury SC; Gilmore RC; Shukla V
Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
[TBL] [Abstract][Full Text] [Related]
31. Detection of
Borkowska EM; Barańska M; Kowalczyk M; Pietruszewska W
Biomolecules; 2021 May; 11(6):. PubMed ID: 34072735
[TBL] [Abstract][Full Text] [Related]
32. Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Qiu W; Tong GX; Manolidis S; Close LG; Assaad AM; Su GH
Int J Cancer; 2008 Mar; 122(5):1189-94. PubMed ID: 17990317
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.
Tillman BN; Yanik M; Birkeland AC; Liu CJ; Hovelson DH; Cani AK; Palanisamy N; Carskadon S; Carey TE; Bradford CR; Tomlins SA; McHugh JB; Spector ME; Brenner JCh
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1646-52. PubMed ID: 26849095
[TBL] [Abstract][Full Text] [Related]
34. Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up.
Vivenza D; Monteverde M; Lattanzio L; Tonissi F; Astesana V; Denaro N; Comino A; Russi E; Lo Nigro C; Merlano M
Int J Biol Markers; 2016 May; 31(2):e183-92. PubMed ID: 26916894
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.
Bumrungthai S; Munjal K; Nandekar S; Cooper K; Ekalaksananan T; Pientong C; Evans MF
J Transl Med; 2015 Jul; 13():244. PubMed ID: 26209091
[TBL] [Abstract][Full Text] [Related]
36. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
37. Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Su YY; Chien CY; Luo SD; Huang TL; Lin WC; Fang FM; Chiu TJ; Chen YH; Lai CC; Hsu CM; Li SH
World J Surg Oncol; 2016 Mar; 14():86. PubMed ID: 27001663
[TBL] [Abstract][Full Text] [Related]
38. Molecular profiling of head and neck squamous cell carcinoma.
Feldman R; Gatalica Z; Knezetic J; Reddy S; Nathan CA; Javadi N; Teknos T
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1625-38. PubMed ID: 26614708
[TBL] [Abstract][Full Text] [Related]
39. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma.
Lièvre A; Blons H; Houllier AM; Laccourreye O; Brasnu D; Beaune P; Laurent-Puig P
Br J Cancer; 2006 Mar; 94(5):692-7. PubMed ID: 16495928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
